Merck KGaA - Company Profile

Powered by

All the sales intelligence you need on Merck KGaA in one solution.

$395 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Merck KGaA fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Merck KGaA.

Back to companies

Merck KGaA: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

View more

Merck KGaA (Merck), a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops, and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. It also offers products such as lab water systems, gene editing tools, cell lines, antibodies, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments, and end-to-end systems. Merck's products and services cater to research and diagnostic labs, biotech and pharmaceutical companies, and life sciences companies, among others, in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Merck is headquartered in Darmstadt, Hessen, Germany.

 Gain a 360-degree view of Merck KGaA and make more informed decisions for your business Gain a 360-degree view of Merck KGaA and make more informed decisions for your business Learn more
Headquarters Germany
Address Frankfurter Strasse 250, Darmstadt, Hessen, 64293
Website www.merckgroup.com
Telephone 49 615 1720
No of Employees 62,477
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange MRK (ETR)
Revenue (2024) $23.8B -0.3% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ -6.1% (2024 vs 2023)
Market Cap* $69.1B
Net Profit Margin (2024) XYZ -5.8% (2024 vs 2023)
* As of and is in US$
View Merck KGaA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Merck KGaA premium industry data and analytics

930+

Clinical Trials

Determine Merck KGaA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

380+

Catalyst Calendar

Proactively evaluate Merck KGaA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

350+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Merck KGaA’s relevant decision makers and contact details.

190+

Marketed Drugs

Understand Merck KGaA’s commercialized product portfolio to stay one step ahead of the market.

160+

Pipeline Drugs

Identify which of Merck KGaA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

70+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Merck KGaA and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Merck KGaA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Merck KGaA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Prescription Drugs: Single-use Manufacturing Apaisyl
Oncology Sterile Filtration AAViator
Neurology & Immunology Filtration Bion
XYZ XYZ XYZ
XYZ XYZ XYZ
XYZ XYZ XYZ
Understand Merck KGaA portfolio and identify potential areas for collaboration Understand Merck KGaA portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2026 Corporate Changes/Expansions In July, the company launched a new EUR25 million BioReliance testing facility at its global headquarters in Darmstadt, Germany.
2026 Contracts/Agreements In June, the company signed an agreement to acquire Bio-Techne for US$11.3 billion.
2026 Corporate Changes/Expansions In May, the company opened its new Metrology & Inspection site in Saint-Ismier, France.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Merck KGaA AstraZeneca Plc Novartis AG Sanofi Bayer AG
Headquarters Germany United Kingdom Switzerland France Germany
City Darmstadt Cambridge Basel Paris Leverkusen
State/Province Hessen Cambridgeshire Basel-Stadt Ile-de-France Nordrhein-Westfalen
No. of Employees 62,477 96,100 75,267 76,493 87,757
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Michael Kleinemeier Chairman Executive Board 2024 69
Kai Beckmann Chief Executive Officer Senior Management 2026 -
Helene von Roeder Chief Financial Officer Senior Management 2023 56
Khadija Ben Hammada Chief People Officer Senior Management 2025 46
Anne Lange Vice Chair Executive Board 2025 42
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Merck KGaA key executives to enhance your sales strategy Gain insight into Merck KGaA key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?